Cingulate Therapeutics
About Cingulate Therapeutics
Cingulate Therapeutics, LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).YEAR FOUNDED:
Dec. 1, 2012
LEADERSHIP:
Founder and CEO: Shane J. Schaffer
Founder and CSO: Raul R. Silva
Founder and CFO: Craig S. Tashjy
30 articles with Cingulate Therapeutics
-
Cingulate Benzinga All Live Access Appearance Rescheduled for December 16
12/1/2022
Cingulate Inc. announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on Friday December 16, 2022, at 9:20 a.m. CST.
-
Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
11/14/2022
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended September 30, 2022 and provided a clinical and business update.
-
Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update
10/24/2022
Cingulate Inc. announced it has executed a Master Services Agreement with Societal CDMO, Inc., a bi-coastal contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development.
-
Cingulate to Present at LD Micro Investor Conference
10/20/2022
Cingulate Inc. (NASDAQ: CING) today announced that Cingulate Chairman & CEO Shane J. Schaffer will present at the LD Micro Main Event XV investor conference on October 26, 2022.
-
Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103
9/19/2022
Cingulate Inc. announced findings from its formulation study for CTx-2103, the Company’s asset for the management of anxiety-related disorders.
-
Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
8/11/2022
Cingulate Inc. announced its financial results for the quarter ended June 30, 2022, and provided a clinical and business update.
-
Kansas City Business Journal Names Cingulate’s Louis G. Van Horn a 2022 Chief Financial Officer of the Year
7/25/2022
Cingulate Inc. announced that Chief Financial Officer, Lou Van Horn, has been named a 2022 CFO of the Year by the Kansas City Business Journal.
-
MindMed, Scripps Research, Cingulate Therapeutics and the University of Pennsylvania discuss innovative treatments on the horizon for the treatment of anxiety disorder.
-
Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders
6/23/2022
Cingulate Inc. today announced completion of the formulation study for its third asset, CTx-2103, for the management of anxiety-related disorders.
-
Cingulate to Present at Diamond Equity Research 2022 Virtual Emerging Growth Invitational
6/17/2022
Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and Chief Executive Officer, Shane J. Schaffer, PharmD, will present a company overview at the Diamond Equity Research 2022 Virtual Emerging Growth Invitational on Thursday, June 23, 2022.
-
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
6/2/2022
Cingulate Inc. announced that Chairman and CEO Shane J. Schaffer, PharmD, and preeminent board-certified psychiatrist and Cingulate scientific advisor Dr. Ann Childress, MD, will participate in a live Benzinga All Access event on June 3, 2022, at 8:45 a.m. CST.
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders
5/24/2022
Cingulate Inc. announced the Company has completed enrollment in its study to determine the appropriate formulation of its third asset, CTx-2103, for the management of anxiety-related disorders.
-
Cingulate to Present at H.C. Wainwright Global Investment Conference
5/18/2022
Cingulate Inc. announced that Chairman and Chief Executive Officer, Shane J. Schaffer, and Chief Medical Officer, Matthew Brams, M.D., will present a company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, from 3:00-3:30 p.m. ET, at the Fontainebleau Miami Beach Hotel, Miami, FL.
-
Cingulate Inc. Announces Closing of Initial Public Offering
12/10/2021
Cingulate Inc. (“Cingulate” or the “Company”), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation products, today announced the closing of its initial public offering of 4,166,666 shares of common stock and accompanying warrants to purchase 4,166,666 shares of common stock.
-
Cingulate Inc. Announces Pricing of $25.0 Million Initial Public Offering
12/7/2021
Cingulate Inc. (“Cingulate” or the “Company”), today announced the pricing of its initial public offering of 4,166,666 shares of common stock and accompanying warrants to purchase 4,166,666 shares of common stock.
-
Numerous biopharma and life sciences companies have sought to put their stocks up for sale, but this week, two companies opted to pull out their IPO due to concerns over market stability.
-
Experts are predicting a record-breaking rush of IPOs this fall as companies flood to the Nasdaq.
-
Cingulate Therapeutics Presents Results of Pivotal Phase 2 Clinical Trial for Lead ADHD Candidate CTx-1301 at the American Association of Child and Adolescent Psychiatry Annual Meeting
10/26/2020
- Cingulate Therapeutics, a privately-held, clinical-stage, biopharmaceutical company focused on the development of innovative new products for the treatment of Attention Deficit/Hyperactivity
-
Cingulate Therapeutics to Present at Biotech Showcase™ 2019 in San Francisco
1/7/2019
Cingulate Therapeutics LLC announced that Shane J. Schaffer, PharmD, Chairman and CEO of Cingulate Therapeutics, will present at Biotech Showcase 2019 to be held January 6-9, 2019, at the Hilton San Francisco Union Square